Study on the Safety and Effectiveness of Forimtamig-Based Treatments for Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Must be in good general health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Expected to live at least 12 more weeks.
• Have a confirmed diagnosis of multiple myeloma based on specific medical criteria.
• Show signs of disease progression after the last treatment, as determined by a doctor.
• Have measurable disease that can be tracked.
• Any side effects from previous cancer treatments must be mild or resolved.
• Must have adequate organ function as determined by medical tests.

Exclusion Criteria

• Cannot be pregnant, breastfeeding, or planning to become pregnant during the study or within 3 months after the last dose.
• Cannot have plasma cell leukemia with a high number of circulating plasma cells.
• Cannot have known amyloidosis or myelodysplastic syndrome.
• Cannot have had certain antibody treatments within 4 weeks or 5 half-lives of the drug, whichever is shorter.
• Cannot have had other cancer treatments within 14 days before starting forimtamig.
• Cannot have had a solid organ transplant.
• Cannot have an active autoimmune disease or recent flare-up.
• Cannot have a known or suspected chronic Epstein-Barr virus infection.
• Cannot have hepatitis B or C infections.
• Cannot have a known history of HIV.
• Cannot have received live vaccines within one month before starting treatment.
• Must be fully vaccinated for COVID-19 as per local guidelines.
• Cannot have been previously unresponsive to carfilzomib.
• Cannot have stopped carfilzomib due to side effects.
• Cannot have known liver cirrhosis.
• Cannot be eligible for stem cell transplantation at the time of enrollment.